Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this ...

Kathryn Beckermann, MD, PhD, discusses the patient-reported outcomes for tivozanib plus nivolumab from the phase 3 TiNivo-2 ...

The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its ...

William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...